CMS: The application for the new drug listing of Ruxolitinib Phosphate Cream (for vitiligo indication) in Hong Kong has been approved
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, CMS announced that the Pharmacy and Poisons Board of the Government of the Hong Kong Special Administrative Region (PPBHK) approved the new drug application for Ruxolitinib Phosphate Cream on November 4, 2024, and received the drug/product registration certificate on November 5, 2024. The product is used for the treatment of non-segmental vitiligo with facial involvement in adolescents aged 12 and older and adult patients
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments